Syntara Limited (SNT) Fair Value & Analysis
Healthcare · AU · Market cap A$46.9M
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from A$0.0400 to A$0.0187 (−53.3%) since Jun 24, 2026. Share price −26.9% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0210 – A$0.0696 · the A$0.0210 price screens above the A$0.0187 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Syntara Limited (SNT) currently trades at A$0.0210, while our model-based Fair Value estimate is A$0.0187 — implying the stock looks roughly 11.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at A$7.5M. Revenue grew 6.7% year over year. It earns a return on equity of -90.5%. The balance sheet holds a net cash position of A$15.0M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and is in Phase 1c/2 studies for patients with myelodysplastic syndrome. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a Phase 1a/b study for hypertrophic scars; SNT-6302 for keloid scars; and SNT-4728 to treat sleep disorders and slow progression of neurodegenerative diseases by reducing neuroinflammation. In addition, it develops other drug candidates that target fibrotic and inflammatory diseases, including kidney fibrosis, MASH, pulmonary fibrosis, and cardiac fibrosis. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Syntara Limited reported revenue of A$7.5M in FY2025 versus A$7.4M in FY2021, a compound +0.2%/yr. Reported net income was −A$7.9M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Syntara Limited (SNT) undervalued?
What is the fair value of SNT?
What is the quality score of SNT?
What is the revenue of Syntara Limited (SNT)?
What is the net profit margin of SNT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.